193001-80-8

Basic information

• Product Name: 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline
• Synonyms: 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline
• CAS NO: 193001-80-8
• Molecular Weight: 410.832
• Mol File: 193001-80-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline(193001-80-8)
• EPA Substance Registry System: 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline(193001-80-8)

Safety Data

• Hazardous Substances Data: 193001-80-8(Hazardous Substances Data)

Upstream product

• 348-62-9 4-chloro-2-fluorophenol 
• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 193001-44-4 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride 

Downstream Products

• 193001-79-5 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline 
• 288384-73-6 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline trifluoroacetate 

Relevant articles and documents

Quinazoline derivatives with anti-tumour activity

The invention concerns quinazoline derivatives of Formula I wherein each of m, R1, n, R2 and R3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

Chemical compounds

The invention relates to quinazoline derivatives of the formula: [wherein: Y1represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R8and R9each independently represents hydrogen, alkyl or alkoxyalkyl); R1represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino. R2represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro; m is an integer from 1 to 5; R3represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.